SCHEMBL31415641

SCHEMBL31415641

N#CCc1cc(Cl)ccc1Br

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.49
CSNK2A1 P68400 5/20 0.42
NOS3 P29474 2/20 0.39
NOS1 P29475 2/20 0.39
NOS2 P35228 2/20 0.39
IDO1 P14902 3/20 0.36
MAPT P10636 3/20 0.36
LMNA P02545 3/20 0.36
CYP3A4 P08684 2/20 0.36
HTT P42858 2/20 0.36
HIF1A Q16665 2/20 0.36
HPGD P15428 2/20 0.36
MEN1 O00255 1/20 0.36
SLC22A1 O15245 1/20 0.36
USP2 O75604 1/20 0.36
HSP90AA1 P07900 1/20 0.36
HSPD1 P10809 1/20 0.36
HSPA5 P11021 1/20 0.36
ALOX15 P16050 1/20 0.36
ALOX12 P18054 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6122855 1.00 CYP2A6 (0.49) CYP2A6CSNK2A1NOS3NOS1NOS2
SCHEMBL1569635 0.84 CYP2A6 (0.49) CYP2A6CSNK2A1IDO1MAPTLMNA
SCHEMBL11339655 0.81 CYP2A6 (0.53) CYP2A6CSNK2A1NOS3NOS1NOS2
SCHEMBL28018344 0.80 NOS3 (0.39) CYP2A6NOS3NOS1NOS2IDO1
SCHEMBL30453664 0.79 CYP2A6 (0.51) CYP2A6CSNK2A1IDO1MAPTLMNA
SCHEMBL28856582 0.79 CSNK2A1 (0.51) CYP2A6CSNK2A1NOS3NOS1NOS2
SCHEMBL2581205 0.79 CYP2A6 (0.51) CYP2A6CSNK2A1IDO1MAPTLMNA
SCHEMBL836823 0.78 CYP2A6 (0.50) CYP2A6CSNK2A1IDO1MAPTLMNA
SCHEMBL2560634 0.76 NOS3 (0.44) CYP2A6NOS3NOS1NOS2IDO1
SCHEMBL7024324 0.76 HIF1A (0.54) NOS3NOS1NOS2IDO1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747251-A1 APOL1 INHIBITORS AND METHODS OF USE Maze Therapeutics, Inc. (US) 2026-05-27 EP disclosed
WO-2025125688-A2 NOVEL COMPOUNDS FOR TARGETED PROTEIN DEGRADATION AMPHISTA THERAPEUTICS LIMITED (GB) 2025-06-19 WO disclosed
WO-2025019479-A1 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2025-01-23 WO disclosed